Independent Innovation Achieves New Breakthrough as Cell Valley Group Deepens CAR-T Technology Patent Portfolio

Recently, the independently developed invention patent of Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd., titled "BCMA-Targeted Chimeric Antigen Receptor, Its T Cells, and Applications," passed substantive examination and was granted authorization by the China National Intellectual Property Administration.

This invention centers on innovation in BCMA-targeted CAR-T cell therapy technology, constructing a novel chimeric antigen receptor structure composed of two tandem humanized BCMA-targeting heavy chain variable regions (VH). Unlike conventional CAR designs that employ a complete ScFv structure, this technology does not include the ScFv light chain VL. By achieving tandem VH linkage through a specific connecting structure, it reduces potential immunogenicity while covering multiple antigenic epitopes on the tumor cell surface, offering a new technical pathway for mitigating tumor immune escape and further enhancing CAR-T cell antitumor activity.

Preliminary research findings indicate that the optimal heavy chain recombinant structure identified through this invention demonstrates excellent tumor cell killing capacity, reflecting the Cell Valley Group's sustained independent innovation capabilities in novel CAR structure design, humanized antibody screening, and cell therapy product development.

BCMA is a critical target for cell therapy in B-cell-related malignancies such as multiple myeloma. The authorization of this invention patent further strengthens the Cell Valley Group's proprietary intellectual property system in CAR-T core structure design, antibody discovery, cell engineering, and tumor immunotherapy, while also laying an important foundation for the subsequent R&D and translation of innovative BCMA CAR-T technologies.

In recent years, the Cell Valley Group has continuously pursued independent R&D in key cell and gene therapy technologies, steadily reinforcing its core technology and intellectual property portfolio across immune cell therapies including CAR-T and CAR-NK, as well as viral vectors and gene editing. Going forward, the Group will remain committed to independent innovation, accelerate the R&D and translation of cell and gene therapy technologies with proprietary intellectual property, and contribute to the high-quality development of China's cell and gene therapy industry through more original technological achievements.